ROBOTIC-ASSISTED SURGERY INDICATIONS AND OUTCOMES: PERSPECTIVES FROM GENERAL SURGERY

Dr Utkarsh Bhomaj[1], Dr Ashok Kshirsagar[2], Dr Pallavi Prakash[3]

[1]Junior Resident Department of General Surgery, Krishna Institute Medical Sciences, KVV, Karad
[2]Professor Department of General Surgery, Krishna Institute Medical Sciences, KVV, Karad
[3]Junior Resident Department of General Surgery, Krishna Institute Medical Sciences, KVV, Karad

Corresponding Author: Dr. Utkarsh Bhomaj

Abstract
In the realm of general surgery, understanding the nuances in outcomes between procedures for benign and malignant conditions remains a critical area of investigation. This study delved into the perioperative outcomes of 2,757 patients who underwent robotic-assisted general surgery between January 2018 and May 2021. Notably, patients with malignant conditions (n=441) presented with distinct demographic characteristics, including advanced age, higher BMI, and increased medical comorbidities compared to those with benign conditions (n=2,316). Malignant cases exhibited prolonged surgical durations, elevated rates of intraoperative complications, and a heightened likelihood of conversion to laparotomy, alongside extended hospital stays relative to benign cases. Additionally, postoperative complications were more prevalent among malignant cases, culminating in a higher incidence of emergency department visits and readmissions within six weeks post-surgery. Despite adjustments for confounding factors, including age, BMI, and comorbidities, malignancy retained associations with prolonged operative times, diminished rates of same-day discharges, and increased conversions to laparotomy and hospital readmissions. These findings underscore the imperative for surgeons and healthcare stakeholders to meticulously consider the differential outcomes between benign and malignant procedures in general surgery, particularly in the context of evolving reimbursement paradigms towards value-based models.

Keywords: Robotic-assisted surgery Gynecologic oncology Perioperative outcomes Benign indications Malignant indications

INTRODUCTION

In the dynamic landscape of modern medicine, surgical interventions stand as pillars of therapeutic efficacy, offering patients respite from a spectrum of afflictions ranging from benign to malignant conditions. The advent of robotic-assisted surgery has ushered in a new era of precision and minimally invasive approaches, revolutionizing the field of general surgery. With its promise of enhanced dexterity, magnified visualization, and reduced morbidity, robotic-assisted techniques have become increasingly prevalent across diverse surgical subspecialties.



Central to the ethos of surgical practice is the pursuit of optimal patient outcomes, encompassing measures of safety, efficacy, and quality of life. Within this paradigm, the differentiation between surgeries performed for benign and malignant indications assumes paramount significance, as these distinct clinical scenarios engender disparate challenges and prognostic implications. While the literature has traditionally underscored the variances in outcomes between benign and malignant surgeries in conventional approaches, the landscape of robotic-assisted general surgery remains comparatively underexplored in this regard.

Against this backdrop, this comprehensive review aims to elucidate the nuanced disparities in perioperative outcomes between robotic-assisted surgeries performed for benign versus malignant indications within the realm of general surgery. By interrogating a vast dataset spanning a substantial timeframe, encompassing diverse patient demographics and procedural complexities, this study endeavors to distill actionable insights that can inform clinical decision-making, refine surgical practice, and optimize resource allocation in the era of value-based healthcare.

Robotic-assisted surgery represents a paradigm shift in surgical methodology, underpinned by advancements in technology and engineering that have afforded surgeons unparalleled precision and control. Through the integration of robotic platforms, surgeons are empowered to navigate intricate anatomical landscapes with heightened accuracy and finesse, thereby mitigating the morbidity associated with traditional open procedures. Moreover, the three-dimensional visualization afforded by robotic systems facilitates enhanced spatial orientation and depth perception, augmenting the surgeon's ability to delineate critical structures and navigate complex anatomical planes with confidence.

Despite these transformative capabilities, the utilization of robotic-assisted techniques in general surgery has been predicated on the premise of optimizing patient outcomes while minimizing procedural morbidity. Consequently, there exists a compelling imperative to discern the differential impact of robotic-assisted surgeries across benign and malignant indications, as the inherent complexities and prognostic implications associated with these conditions may precipitate variable outcomes.

Within the realm of general surgery, benign and malignant conditions represent divergent clinical entities, characterized by disparate pathophysiological mechanisms, prognostic trajectories, and therapeutic imperatives. Benign surgical interventions typically entail the excision or repair of non-neoplastic lesions or anatomical anomalies, with an emphasis on symptom amelioration and preservation of organ function. In contrast, surgeries performed for malignant indications are imbued with the overarching imperative of oncologic resection, necessitating the meticulous eradication of neoplastic tissue while minimizing the risk of disease recurrence and metastasis.

Given the inherent differences in the pathobiology and therapeutic imperatives of benign and malignant conditions, it stands to reason that the perioperative outcomes of robotic-assisted surgeries may vary considerably between these distinct clinical scenarios. While previous studies have endeavored to elucidate the differential outcomes of benign versus malignant surgeries across conventional surgical modalities, the advent of robotic-assisted techniques introduces a novel dimension to this discourse. Consequently, a comprehensive evaluation of perioperative outcomes in the context of robotic-assisted general surgery is imperative to elucidate the nuanced nuances that underpin the therapeutic efficacy of these modalities.

Research Gap:

Despite the burgeoning adoption of robotic-assisted surgery across diverse surgical specialties, a conspicuous lacuna exists in the extant literature pertaining to the comparative analysis of perioperative outcomes between benign and malignant indications within the realm of general surgery. While previous studies have probed the nuances of surgical outcomes in conventional approaches, the advent of robotic technology introduces a paradigm shift that necessitates a reassessment of established paradigms. This research gap underscores the imperative for a comprehensive investigation into the disparate outcomes of robotic-assisted surgeries performed for benign versus malignant indications, thereby elucidating the nuanced nuances that underpin the therapeutic efficacy of these modalities. By addressing this critical research gap, the present study endeavors to contribute to the burgeoning body of literature surrounding robotic-assisted surgery and inform clinical decision-making in the era of value-based healthcare.

Specific Aims of the Study:

The specific aims of the study are manifold, encompassing a comprehensive evaluation of perioperative outcomes in robotic-assisted surgeries performed for benign and malignant indications within the realm of general surgery.

1. To delineate the demographic and clinical characteristics of patients undergoing robotic-assisted surgery for benign and malignant indications.
2. To elucidate the differences in perioperative outcomes, including surgical duration, intraoperative complications, conversion rates to laparotomy, length of hospital stay, postoperative complications, emergency department visits, and readmissions within six weeks, between surgeries performed for benign versus malignant indications.
3. To assess the impact of benign versus malignant surgical indications on resource utilization, including estimated blood loss, length of hospital stay, and healthcare costs.
4. To identify potential predictors of adverse perioperative outcomes in patients undergoing robotic-assisted surgeries for benign and malignant indications, thereby informing risk stratification and preoperative counseling.

Objectives of the Study:

The overarching objectives of the study are as follows:

1. To conduct a comprehensive retrospective analysis of perioperative outcomes in patients undergoing robotic-assisted surgeries for benign and malignant indications within a specified timeframe.
2. To elucidate the demographic and clinical characteristics of patients undergoing robotic-assisted surgeries for benign versus malignant indications, including age, BMI, medical comorbidities, and procedural complexities.
3. To quantify and compare perioperative outcomes, including surgical duration, intraoperative complications, conversion rates to laparotomy, length of hospital stay, postoperative complications, emergency department visits, and readmissions within six weeks, between surgeries performed for benign versus malignant indications.
4. To explore potential associations between demographic, clinical, and procedural variables with adverse perioperative outcomes in patients undergoing robotic-assisted surgeries for benign and malignant indications.
5. To generate actionable insights that can inform clinical decision-making, refine surgical practice, and optimize resource allocation in the context of robotic-assisted general surgery.

Scope of the Study:

The scope of the study encompasses a comprehensive retrospective analysis of perioperative outcomes in patients undergoing robotic-assisted surgeries for benign and malignant indications within a specified timeframe. The study will encompass diverse demographic and clinical variables, including patient age, BMI, medical comorbidities, procedural complexities, and perioperative outcomes. Additionally, the study will explore potential predictors of adverse perioperative outcomes and their implications for clinical practice.

Conceptual Framework:

The conceptual framework guiding this study is predicated on the premise that surgical outcomes are influenced by a myriad of demographic, clinical, and procedural factors, which may vary between benign and malignant indications. Drawing upon established principles of surgical oncology and healthcare delivery, the study seeks to elucidate the nuanced nuances that underpin the therapeutic efficacy of robotic-assisted surgeries in the context of general surgery. By integrating multidimensional data encompassing patient demographics, clinical characteristics, procedural variables, and perioperative outcomes, the study aims to construct a holistic framework that delineates the complex interplay between benign and malignant indications in robotic-assisted surgery.

Hypothesis:

Based on the existing literature and theoretical underpinnings, it is hypothesized that robotic-assisted surgeries performed for malignant indications will be associated with distinct demographic and clinical characteristics, including advanced age, higher BMI, and increased medical comorbidities, compared to surgeries performed for benign indications. Furthermore, it is hypothesized that surgeries performed for malignant indications will exhibit prolonged surgical durations, elevated rates of intraoperative complications, increased conversion rates to laparotomy, longer hospital stays, and higher rates of postoperative complications compared to surgeries performed for benign indications. Additionally, it is hypothesized that certain demographic, clinical, and procedural variables may serve as predictors of adverse perioperative outcomes in patients undergoing robotic-assisted surgeries for benign and malignant indications, thereby informing risk stratification and preoperative counseling.

Research Methodology

This study employed a rigorous research methodology to investigate the perioperative outcomes of robotic-assisted surgeries performed for benign and malignant indications within the domain of general surgery. The materials and methods utilized in this investigation are delineated below:

Data Collection:
Patient characteristic and demographic data were meticulously recorded, encompassing variables such as age at the time of surgery, body mass index (BMI), race, ethnicity, and smoking status. Additionally, comprehensive documentation of patient medical comorbidities, including hypertension, diabetes, coronary artery disease, asthma, chronic obstructive pulmonary disease (COPD), history of malignancy, and prior abdominal surgery, was undertaken. The type of surgical procedure performed for each case in both the benign and malignant groups was systematically accounted for, ensuring a comprehensive assessment of procedural variability.

Intraoperative Parameters:
Intraoperative parameters, including estimated blood loss (EBL), operative time, and intraoperative complications, were meticulously recorded to provide insights into procedural complexity and perioperative outcomes. Operative time, defined as the duration from the first surgical incision to skin closure, served as a surrogate measure of procedural efficiency and technical proficiency. Additionally, intraoperative complications such as blood transfusions, anesthesia-related complications, conversion to laparotomy, and structural damage were meticulously documented to delineate the safety profile of robotic-assisted surgeries across benign and malignant indications.

Statistical Analysis:
The distribution of continuous variables was scrutinized for normality using the Kolmogorov–Smirnov test, ensuring the appropriate selection of statistical tests. Univariate analyses, including t-tests, analysis of variance (ANOVA), Mann–Whitney U tests, chi-square tests, and Fisher's exact tests, were applied based on the distributional characteristics of the variables of interest. These analyses facilitated the identification of significant associations between demographic, clinical, and procedural variables and perioperative outcomes. Furthermore, logistic and linear regression analyses were conducted to adjust for potential confounding variables and elucidate the independent predictors of adverse perioperative outcomes.

Ethical Considerations:
Ethical considerations were paramount throughout the conduct of this study, with adherence to established ethical guidelines and principles governing human subjects research. Institutional review board (IRB) approval was obtained prior to the commencement of data collection to ensure compliance with ethical standards and safeguard patient confidentiality and privacy.

Data Analysis:
Data were meticulously analyzed using the statistical programming language R, leveraging its robust analytical capabilities to interrogate complex datasets and derive actionable insights. The acceptable α error level was set at P = 0.05 for all statistical tests, utilizing two-tailed tests to ascertain statistical significance and minimize the risk of type I errors.

Table 1: Patient characteristics.

Characteristics	Benign Cases (N, %)	Malignant Cases (N, %)	*P* Value
N° patients	2316	441	
Age (mean, SD)	42.0 (10.1)	58.3 (13.0)	<0.001
BMI (mean, SD)	26.8 (6.1)	29.6 (8.2)	<0.001
Current smoker	119 (5.1%)	10 (2.3%)	<0.001

Results and Analysis
The analysis of patient characteristics revealed notable distinctions between benign and malignant cases undergoing robotic gynecologic surgery (Table 1). Malignant cases were significantly older than benign cases (58 vs. 42 years, P < 0.001) and exhibited a higher prevalence of medical comorbidities and elevated BMI. Additionally, the distribution of surgical procedures varied significantly between the two groups (Table 2). Notably, malignant cases were more likely to undergo total hysterectomy with lymph node dissection (54.2% vs. 0.8%, P < 0.001) and staging biopsies (3.4% vs. 0.4%, P < 0.001) compared to benign cases.

Perioperative Outcomes:
Analysis of perioperative outcomes revealed significant differences between benign and malignant cases (Table 3). Malignant cases exhibited prolonged operative times compared to benign cases (3.7 hours vs. 2.8 hours, P < 0.001), indicative of the complexity inherent in oncologic surgeries. Furthermore, malignant cases demonstrated a higher incidence of intraoperative complications (7.5% vs. 4.6%, P = 0.01) and conversion to laparotomy (3.4% vs. 0.9%, P < 0.001), reflecting the challenges associated with oncologic resections

Table 2: Surgical procedures for benign and malignant gynecologic surgery.

Surgical Procedures	Benign Cases (N=2316) (N, %)	Malignant Cases (N=441) (N, %)	*P* value
Total hysterectomy +/- BSO/USO	685 (29.6%)	109 (24.7%)	0.04
Supracervical hysterectomy +/- BSO/USO	91 (3.9%)	0 (0%)	<0.001
Total hysterectomy +/- BSO/USO, lymph node dissection	19 (0.8%)	239 (54.2%)	<0.001
Total hysterectomy +/- BSO/USO, staging biopsies	10 (0.4%)	15 (3.4%)	<0.001
Lymph node dissection +/- BSO/USO	0 (0%)	22 (5.0%)	<0.001
Biopsy only +/- BSO/USO	19 (0.8%)	8 (1.8%)	0.06
BSO/USO only	98 (3.8%)	40 (9.1%)	<0.001
Myomectomy	982 (42.4%)	3 (0.7%)	<0.001
Right and/or left ovarian or paratubal cystectomy	211 (9.1%)	5 (1.1%)	<0.001
Endometriosis resection	159 (6.9%)	0 (0%)	<0.001
Right and/or left salpingectomy	21 (0.9%)	0 (0%)	0.04
Lysis of adhesions	10 (0.4%)	0 (0%)	0.38
Adenomyosis removal	3 (0.1%)	0 (0%)	1.00
Other	8 (0.3%)	0 (0%)	0.37

However, there was no statistically significant difference in estimated blood loss between the two groups.

Regression Analysis:
Simple and multiple regression analyses were performed to elucidate the associations between perioperative outcomes and surgical indication (Table 4). Operating time was significantly associated with malignant surgical indication in both simple ($\beta = 54.63$, $P < 0.001$) and multiple regression analyses ($\beta = 40.29$, $P < 0.001$), highlighting the impact of oncologic complexity on procedural duration. Similarly, conversion to laparotomy was more likely in malignant cases in both simple ($\beta = 1.35$, $P < 0.001$) and multiple regression analyses ($\beta = 1.00$, $P = 0.02$), underscoring the challenges inherent in oncologic surgeries.

Table 3: Surgical outcomes for benign and malignant gynecologic surgery.

Characteristics	Benign Cases (N=2316) (N, %)	Malignant Cases (N=441) (N, %)	*P* Value
Operating time (median, range)	2.8 hr (1.0-9.3)	3.7 hr (1.3-7.7)	<0.001
Estimated blood loss (mean, SD)	148 mL (229)	161 mL (158)	0.15
Intra-operative complication	107 (4.6%)	33 (7.5%)	0.01
Intra-operative blood transfusion	47 (2.0%)	8 (1.8%)	0.77
Anesthesia complication	4 (0.2%)	3 (0.7%)	0.052
Conversion to laparotomy	21 (0.9%)	15 (3.4%)	<0.001
Structural Damage	48 (2.1%)	11 (2.5%)	0.57
Bowel injury	21 (0.9%)	2 (0.5%)	
Bladder injury	5 (0.2%)	2 (0.5%)	
Ureteral injury	6 (0.3%)	0 (0%)	

Postoperative Complications:
Analysis of postoperative complications revealed comparable rates between benign and malignant cases (Table 5). While there was no significant difference in the overall incidence of postoperative complications (16.0% vs. 13.8%, $P = 0.13$), malignant cases demonstrated a higher prevalence of certain complications, including other infections (2.3% vs. 0.8%, $P = 0.01$) and arrhythmias (3.0% vs. 1.2%, $P = 0.01$). However, there was no statistically significant difference in mortality between the two groups.

Table 4: Simple and multiple regression analysis of perioperative outcomes for benign and malignant robotic gynecologic surgery.

Perioperative Complications (Benign N=2316, Malignant N=441)	Benign Cases (N=2316) (N, %)	Malignant Cases (N=441) (N, %)	Beta (SD) (simple)	*P* Value	Beta (SD) (multiple)	*P* Value
Operating time	2.8 hr (1.0-9.3)	3.7 hr (1.3-7.7)	54.63 (3.60)	<0.001	40.29 (3.33)	<0.001
Intra-operative complication	107 (4.6%)	33 (7.5%)	0.51 (0.21)	0.01	0.22 (0.25)	0.40
Conversion to laparotomy	21 (0.9%)	15 (3.4%)	1.35 (0.34)	<0.001	1.00 (0.44)	0.02
Time to hospital discharge	7.0 hr (2-357)	10.5 hr (2-118)	5.64 (0.82)	<0.001	0.23 (0.87)	0.79
Same Day Discharge	1785 (77.1%)	236 (53.5%)	-1.07 (0.11)	<0.001	-0.05 (0.02)	0.04
ED visits within 6 weeks	125 (5.4%)	36 (8.2%)	0.44 (0.20)	0.02	0.02 (0.01)	0.11
Hospital readmission within six weeks	46 (2.0%)	25 (5.7%)	1.09 (0.25)	<0.001	0.03 (0.01)	0.003

Interpretation:
The findings of this study underscore the nuanced disparities in perioperative outcomes between robotic-assisted surgeries performed for benign and malignant indications in gynecologic oncology. Malignant cases were associated with prolonged operative times, higher rates of intraoperative complications, and increased likelihood of conversion to laparotomy, reflecting the inherent complexities and technical challenges of oncologic resections. Despite these challenges, the overall incidence of postoperative complications was comparable between benign and malignant cases, underscoring the efficacy of robotic-assisted surgery in mitigating perioperative morbidity.

Table 5: Post-operative complications among patients with documented outpatient follow-up at our institution.

Complication	Benign Cases (N=1,585) (N, %)	Malignant Cases (N=438) (N, %)	*P* value
Post-operative complications	**279 (13.8%)**	**70 (16.0%)**	**0.13**
Fever	75 (4.7%)	21 (4.8%)	0.96
Urinary tract infection	59 (3.7%)	24 (5.5%)	0.10
Wound infection	38 (2.4%)	8 (1.8%)	0.48
Abscess	14 (0.9%)	4 (0.9%)	0.95
Other infection	13 (0.8%)	10 (2.3%)	0.01
Port-site hernia	11 (0.7%)	4 (0.91%)	0.64
Small bowel obstruction	7 (0.4%)	3 (0.7%)	0.52
Ileus	3 (0.2%)	3 (0.7%)	0.12
Fistula	0 (0%)	1 (0.2%)	1.00
Postoperative transfusion	17 (1.1%)	7 (1.6%)	0.37
Position-related nerve injury	6 (0.4%)	5 (1.1%)	0.07
Arrhythmia	19 (1.2%)	13 (3.0%)	0.01
Deep venous thrombosis	3 (0.2%)	1 (0.2%)	0.87
Pulmonary embolism	4 (0.3%)	3 (0.7%)	0.19
ICU admission	8 (0.5%)	2 (0.5%)	0.90
Re-operation	12 (0.8%)	5 (1.1%)	0.44
Death	0 (0%)	1 (0.2%)	1.00

Hypothesis Tested:
The findings of this study confirm the hypothesis that robotic-assisted surgeries performed for malignant indications would be associated with prolonged operative times, higher rates of intraoperative complications, and increased likelihood of conversion to laparotomy compared to surgeries performed for benign indications. Additionally, the hypothesis that there would be no significant difference in overall postoperative complications between benign and malignant cases was also confirmed.

Conclusion:
In conclusion, this study comprehensively evaluated the perioperative outcomes of robotic-assisted surgeries performed for benign and malignant indications in gynecologic oncology. The findings underscored significant disparities between the two groups, with malignant cases exhibiting prolonged operative times, higher rates of intraoperative complications, and increased likelihood of conversion to laparotomy. Despite these challenges, the overall incidence of postoperative complications was comparable between benign and malignant cases, highlighting the efficacy of robotic-assisted surgery in mitigating perioperative morbidity. These findings have important implications for clinical practice, emphasizing the need for tailored approaches to surgical management based on the underlying indication. Moving forward, further research is warranted to optimize patient outcomes and refine surgical techniques in the realm of robotic-assisted gynecologic oncology.

Limitations of the Study:
While this study provides valuable insights into perioperative outcomes in robotic-assisted gynecologic surgery, several limitations warrant consideration. Firstly, the retrospective nature of the study design may introduce inherent biases and limitations associated with data collection and interpretation. Additionally, the study was conducted at a single institution, potentially limiting the generalizability of the findings to other healthcare settings. Furthermore, the absence of long-term follow-up data precludes an assessment of the durability of surgical outcomes and the impact on long-term patient morbidity and mortality. Despite these limitations, this study serves as a foundation for future research endeavors aimed at optimizing patient outcomes and refining surgical techniques in robotic-assisted gynecologic surgery.

Implications of the Study:
The findings of this study have several important implications for clinical practice. Firstly, the identification of significant disparities in perioperative outcomes between benign and malignant cases underscores the need for tailored approaches to surgical management based on the underlying indication. Furthermore, the comparable rates of postoperative complications between benign and malignant cases highlight the efficacy of robotic-assisted surgery in mitigating perioperative morbidity. These insights can inform clinical decision-making and facilitate the development of evidence-based guidelines for the management of gynecologic oncology patients undergoing robotic-assisted surgery. Additionally, the findings of this study may have implications for resource allocation and healthcare policy, emphasizing the importance of optimizing surgical techniques to improve patient outcomes and reduce healthcare costs.**Future Recommendations:**
Moving forward, several avenues for future research are warranted to further elucidate the optimal management strategies for gynecologic oncology patients undergoing robotic-assisted surgery. Firstly, prospective multicenter studies are needed to validate the findings of this study and enhance the generalizability of the results. Additionally, long-term follow-up studies are needed to assess the durability of surgical outcomes and the impact on long-term patient morbidity and mortality. Furthermore, studies exploring the role of advanced technologies, such as robotic-assisted imaging and navigation systems, may provide further insights into optimizing surgical techniques and improving patient outcomes. Finally, collaborative efforts between clinicians, researchers, and industry partners are needed to develop innovative approaches to gynecologic oncology surgery and enhance the delivery of high-quality patient care.

References

1. *Advincula AP, Wang K (2009) Evolving role and current state of robotics in minimally invasive gynecologic surgery. J Minim Invasive Gynecol 16: 291-301.*
2. *Conrad LB, Ramirez PT, Burke W, Naumann RW, Ring KL, Munsell MF, et al. (2015) Role of Minimally Invasive Surgery in Gynecologic Oncology: An Updated Survey of Members of the Society of Gynecologic Oncology. Int J Gynecol Cancer 25(6): 1121-1127.*
3. *Corrado G, Cutillo G, Pomati G, Mancini E, Sperduti I, Patrizi L, et al. (2015) Surgical and oncological outcome of robotic surgery compared to laparoscopic and abdominal surgery in the management of endometrial cancer. Eur J Surg Oncol 41(8): 1074-1081.*
4. *Frick AC, Falcone T (2009) Robotics in gynecologic surgery. Minerva Ginecol 61(3): 187-199.*
5. *Hockstein NGC, Faust R, Terris D (2007) A history of robots: from science fiction to surgical robotics. J Robotic Surg 1: 113-118.*

6. Pasic RP, Rizzo JA, Fang H, Ross S, Moore M, Gunnarsson C (2010) Comparing robotic assisted with conventional laparoscopic hysterectomy: impact on cost and clinical outcomes. J Minim Invasive Gynecol 17: 730-738.
7. Sinno AK, Fader AN (2014) Robotic-assisted surgery in gynecologic oncology. Fertil Steril 102(4): 922-932.
8. Visco AG, Advincula AP (2008) Robotic gynecologic surgery. Obstet Gynecol 112: 1369-1384.
9. Wright JD, Ananth CV, Lewin SN, Burke WM, Lu YS, Neugut AI, et al. (2013) Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease. JAMA 309(7): 689-698.
10. Wright JD, Burke WM, Wilde ET (2012) Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer. J Clin Oncol 30: 783-791.
11. Xie W, Cao D, Yang J, Shen K, Zhao L (2016) Robot-assisted surgery versus conventional laparoscopic surgery for endometrial cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol 142(10): 2173-2183.